Indivior Share Discussion Threads

[gregmorg] 07/12/2022 11:52

Ah, Steeplejack we remember those days eh!
So, who knows, we might see those numbers again. From what I have briefly scanned it looks rather more encouraging so here’s hoping. I assume I will be able to see parts of the presentation and slides in a few days time when back at base.

[steeplejack] 07/12/2022 11:23

The shares all time high was set around May 2018.In new money,that high was around £24.

[grupo guitarlumber] 07/12/2022 07:52

07 December 2022

Indivior Capital Markets Day Highlights Strategy for Shareholder Value Creation

and Attractive Medium-Term Profitable Growth Outlook

- Peak Annual Net Revenue Potential for SUBLOCADE (R) Increased to >$1.5 Billion

- Attractive and Scalable Business Outlined - Expects Strong Net Revenue Growth and Operating Margin Expansion Over the Medium-term

- Disciplined Approach to Capital Allocation Maintained

- NASDAQ Listing Targeted for Spring 2023

This Release Contains Inside Information.

Slough, UK, and Richmond, VA, December 7, 2022 - Indivior PLC (LON: INDV) will hold a Capital Markets Day today in New York City. The event will be hosted by Mark Crossley, Chief Executive Officer, along with members of the Indivior executive leadership team and will detail the Company's strategic growth plans and roadmap for delivering long-term shareholder value.

"We have made tremendous progress executing on our strategic priorities," said Mark Crossley. "We are the pioneer and global leader in addiction treatment and science and are well-positioned to transform the lives of the increasing number of patients affected by the opioid crisis, one of the most urgent public health emergencies of our time. Today, my team and I are excited to provide a deep review of our business and to highlight the compelling opportunities we have to innovate in the treatment of addiction and serious mental illness while delivering profitable growth and significant value creation for shareholders."

-- Increases SUBLOCADE peak annual net revenue (NR) expectations to >$1.5 billion

Indivior expects SUBLOCADE(R) (buprenorphine extended-release) injection to achieve a NR run rate of $1 billion by the end of 2025, driven by its focus on further developing the Organized Health Systems (OHS) channel and pursuing the large opportunity in the U.S. Justice System. Longer term, based on the expected positive market dynamics for buprenorphine medication-assisted treatment (BMAT) and on continued execution against its OHS strategy, Indivior now expects to deliver SUBLOCADE peak potential NR of >$1.5 billion.

-- Expects to achieve attractive double-digit % NR compounded annual growth rate (CAGR) over the medium-term

Indivior expects to achieve a double-digit percentage NR CAGR over the medium-term, driven primarily by SUBLOCADE in the United States and growing NR contribution from PERSERIS(R) (risperidone for extended-release injection). Within this outlook, which is based on its current business portfolio, Indivior also expects a return to NR growth in the Rest of the World driven by new products SUBLOCADE (SUBUTEX (R) PR) and SUBOXONE (R) (buprenorphine/naloxone) Film. Additionally, the Company assumes the U.S. market share of SUBOXONE Film, which it does not promote, will trend towards historical analogs for genericized medicines.

-- Operating margin expansion opportunity from scalable business model

Indivior expects to achieve significant operating margin expansion over the medium-term driven by an improving gross margin and focused management of operating expenses. Following the significant structural growth investments behind SUBLOCADE and PERSERIS in the past two years, selling, general and administrative (SG&A) expenses are expected to grow at a more moderate pace and to decline as a percentage of NR. This impact is expected to be partly offset by an increase in R&D expenses as a percentage of NR towards industry benchmarks as the Company seeks to build a strong and balanced pipeline focused on addiction treatments.

-- Disciplined capital allocation approach focused on driving growth and potential returns of excess cash

In the past two years, Indivior's healthy balance sheet and improved cash flow have supported a balanced approach towards capital allocation, focused on investment in key growth priorities, diversifying the business, delivering shareholder returns and meeting other stakeholder obligations. The recently announced definitive agreement to acquire Opiant Pharmaceuticals, Inc. (NASDAQ: OPNT) is indicative of Indivior's commitment to diversify its product portfolio and to expand its global leadership in addiction treatment and science.

-- Listing on NASDAQ targeted for the Spring of 2023

At its Extraordinary General Meeting (EGM) in September of this year, Indivior received strong support from its shareholders for an additional share listing in the United States. Having carefully evaluated the available options, Indivior has chosen NASDAQ as its U.S. trading venue. The additional listing is expected to elevate Indivior's profile in the Company's largest market and to attract a broader group of biopharma-focused investors and analysts.

The Group reiterates its FY 2022 guidance published on October 27, 2022.

Event Details

Today's event will begin at 8:30am EST and conclude at 12:30pm EST. Due to limited availability, in-person participation is limited to institutional investors and analysts. For those wishing to attend in person, please RSVP to [e-mail] and further location details will be provided.

Further details can be found at cmd.indivior.com

To access the live webcast, please click INDV CMD 2022 .

A webcast replay will be available after the event has concluded.

The person responsible for making this announcement is Kathryn Hudson, Company Secretary.

[youngers] 05/12/2022 16:56

Something funny going on here. Late reported trade every evening making the closing price look much lower than reality.

[redwing1] 02/12/2022 08:53

And by the way, 'shorting' is just another market strategy - it doesn't make a company "not nice". If shorters get it wrong they lose money, just like long only funds can do.

[redwing1] 02/12/2022 08:49

Timmy11 - It might help if you actually understood shorting. The clue is in the name and it means selling stock you don't have in the expectation of buying it back at a lower price later on for a profit. Therefore Blackrock are simply buying right now. Whether they end up 'pumping and dumping' is another story - we shall see.

[steeplejack] 23/11/2022 18:15

A good observation

[timmy11] 23/11/2022 15:35

i am wary of BlackRock, they usually buy to short... not a nice company

[casholaa] 23/11/2022 11:57

GLA. DYOR.

[steeplejack] 23/11/2022 08:21

SocGen have upped their interest by around 1.25% to over 5% while Blackrock now have a similarly sized declarable stake.All very encouraging.

[casholaa] 22/11/2022 22:53

There's two rns not showing up here ...you may want to track them down.

:o)

[youngers] 21/11/2022 16:32

Good to see this finally break the £17 mark today. Hopefully set for another leg higher from here

[gregmorg] 15/11/2022 09:41

Yup, the odd "extra string to the bow" does not go amiss. Although small (currently!) it's potentially a nice acquisition.

[casholaa] 14/11/2022 13:58

Very nice.

[the grumpy old men] 14/11/2022 08:30

Indivior to buy US overdose treatment firm Opiant for $145m

Mon, 14th Nov 2022 07:05
Sharecast News

(Sharecast News) - UK-based drug company Indivior said it would pay $145m for Opiant Pharmaceuticals which produces treatments to overcome opioid addiction.

The price equates to $20 a share, with an extra $8 per share contingent on Opiant's ability to gain approvals and revenue for an overdose-reversal medication in late-stage development.

Opiant contributed to the development of the formulation of Narcan nasal spray, a treatment to reverse opioid overdose. It is also developing potential treatments for alcohol drinking and cravings acute cannabinoid overdose.

The US government

has pledged $1.5bn to treat its growing the overdose crisis and billions from lawsuit settlements against pharmaceutical companies that made the opioids have begun flowing to local governments to combat deaths.

Reporting by Frank Prenesti for Sharecast.com

[steeplejack] 28/10/2022 07:10

Its more than likely that the Stock Exchange finds the RNS sitting in their “in tray” and decides to release the figures there and then with no regard to the planned time of release.Once the ADRs have been issued,maybe the Stock Exchange will grasp that there is logic behind the company’s desire to release information when the US is up and about.

[waldron] 27/10/2022 11:47

TOP NEWS: Indivior ups annual guidance on "strong momentum"

Thu, 27th Oct 2022 11:05
Alliance News

(Alliance News) - Indivior PLC on Thursday reported a double-digit rise in both quarterly net revenue and profit, as it raises its full-year guidance.

For the third quarter of 2022, the Richmond, Virginia-based pharmaceutical

firm reported net revenue of USD232 million, up 24% from USD187 million a year ago. It said net revenue growth was primarily driven by Sublocade.

Pretax profit increased by 74% to USD54 million from USD31 million. Operating income went up by 47% to USD56 million from USD38 million a year earlier.

Chief Executive Officer Mark Crossley said: "I am pleased to report another strong quarter of top-and bottom-line performance, led by our long-acting injectable medicines, Sublocade and Perseris, which are benefiting from the strategic investments we have made over the past year."

Sublocade is a prescription medicine used to treat adults with opioid drugs addiction, while Perseris reduces symptoms of schizophrenia in adults.

Indivior said Sublocade exceeded the USD100 million milestone in quarterly net revenue "for the first time from continued strong execution against [its] Organized Health Systems strategy".

Its net revenue for 2022 is expected to be in the range of USD405 million to USD420 million, up 69% from USD390 million to USD420 million in 2021 at mid-point.

For the nine months that ended on September 30, total net revenue increased by 16% to USD659 million from USD568 million a year ago.

Looking ahead, Indivior lifted its 2022 net revenue guidance to a range of USD890 million to USD915 million, up 14% from USD840 million to USD900 million at the midpoint a year ago, based on "continued strong momentum of the business

".

It also expects adjusted operating income to be broadly similar to 2021's adjusted operating income of USD187 million, driven by the continued strong Sublocade growth.

Shares were up 1.8% at 1,636.00 pence each on Thursday morning in London.

In July, Indivior posted a 11% slip in pretax profit to USD106 million for the six months ended June 30, from USD119 million the same period a year earlier, even as net revenue rose 12% to USD428 million from USD381 million.

By Xindi Wei; [e-mail]

[youngers] 27/10/2022 11:39

Great results and my only gripe is again they said being released at 7am US time but then released 7am U.K. time. Someone needs to explain time zones to them

[casholaa] 27/10/2022 11:21

Yeah, Truss + Kwatang went and gave all them barristers a pay rise.

[the grumpy old men] 27/10/2022 11:03

Michele Maatouk
Sharecast News
27 Oct, 2022 10:35
Indivior ups FY guidance after solid third quarter

In the three months to 30 September, net income jumped 52% to $41m, while adjusted operating profit was 53% higher at $58m. Net revenue grew 24% to $232m, driven mainly by injectable opioid treatment Sublocade.

Chief executive Mark Crossley said: "I am pleased to report another strong quarter of top- and bottom-line performance, led by our long-acting injectable medicines (LAIs), Sublocade (buprenorphine extended-release) and Perseris (risperidone), which are benefiting from the strategic investments we have made over the past year.

"Sublocade, our paradigm shift in the treatment of opioid use disorder (OUD), exceeded the $100m milestone in quarterly net revenue for the first time from continued strong execution against our Organized Health Systems (OHS) strategy. Additionally in the quarter, we took an important strategic step to elevate the group's profile in its highest value market and attract a broader group of biopharma-focused investors with shareholder approval of an additional listing, which will be in the US."

Based on its overall performance to date and a strong outlook for Sublocade, the group lifted its total net revenue and adjusted operating profit guidance. It now expects FY 2022 net revenue of between $890m and $915m, up from previous guidance of $840m to $900m. Meanwhile, adjusted operating profit is expected to be to be "modestly higher" than 2021.

"A key component of this increase is driven by the continued strong Sublocade growth in the OHS channel leading to narrower guidance of $405m-$420m representing the upper half of updated guidance provided at the half year," it said.

[casholaa] 27/10/2022 08:32

Stellar imho. dyor. gla.

[steeplejack] 27/10/2022 08:25

These are very good results.I suspect the MMs would like to have given the shares a good tonking after recent strength but these figures undermine their bad intentions.Guidance raised,share buyback programme still has around $33m to go,being some two thirds completed.

[adrian j boris] 25/10/2022 11:53

Calendar
10/27 | 12:00pm Earnings Release